Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

  • STATUS
    Recruiting
  • End date
    Dec 31, 2022
  • participants needed
    50
  • sponsor
    Xuanwu Hospital, Beijing
Updated on 15 June 2022

Summary

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke.

Details
Condition Acute Ischemic Stroke
Treatment dimethyl fumarate
Clinical Study IdentifierNCT04890366
SponsorXuanwu Hospital, Beijing
Last Modified on15 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

more than 18years old
NIHSS score≥5
MRI shows anterior circulation infarction
Patients who meet Alteplase thrombolytic therapy within 4.5h
The time from onset to DMF application was less than 24 hours

Exclusion Criteria

Hemorrhagic stroke
Patients who have received or plan to receive endovascular therapy
Other diseases of the central nervous system
Pre-existing neurological disability (mRS Score >2)
Vertebrobasilar artery obstruction
Difficulty swallowing
Patients who cannot accept MRI examination
Abnormal liver function (transaminase higher than 2 times the normal upper limit)
The lymphocyte count was lower than the lower limit of normal value
Anti-tumor drugs, other immunosuppressive and immunomodulatory drugs are being used
Patients known to have hypersensitivity to dimethyl fumarate or any excipients
Pregnant and lactating women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note